Instrument Inactif

Communiqués Pardes Biosciences, Inc.

Actions

PRDS

US69945Q1058

Communiqués

27/12/21	FS II : Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19 - Form 8-K	PU
27/12/21	PARDES BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23/12/21	PARDES BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)	AQ
23/12/21	FS DEVELOPMENT CORP. II : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
21/12/21	FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections	BU
21/12/21	FS II : FSII and Pardes Biosciences Move Towards Merger with the Goal of Tackling COVID-19 Via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections - Form 8-K	PU
21/12/21	FS DEVELOPMENT CORP. II : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
17/12/21	FS II : Material Event - Form 8-K	PU
17/12/21	FS DEVELOPMENT CORP. II : Other Events (form 8-K)	AQ
01/12/21	FS Development II : Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021 - Form 8-K	PU
01/12/21	FS DEVELOPMENT CORP. II : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/12/21	FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021	BU
23/11/21	FS DEVELOPMENT CORP. II Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q/A)	AQ
23/11/21	FS DEVELOPMENT CORP. II : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	AQ
18/11/21	FS DEVELOPMENT CORP. II : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
12/11/21	FS DEVELOPMENT CORP. II Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
09/11/21	FS DEVELOPMENT CORP. II : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
26/08/21	FS Development II : Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections	AQ
16/08/21	FS DEVELOPMENT II : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
29/06/21	FS Development II : Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections (Form 8-K)	PU
29/06/21	FS DEVELOPMENT CORP. II : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
29/06/21	FS Development II : Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections	BU
17/05/21	FS DEVELOPMENT II : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
25/02/21	FS DEVELOPMENT CORP. II : Other Events (form 8-K)	AQ
19/02/21	FS DEVELOPMENT CORP. II : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events (form 8-K)	AQ